

This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction (PGD)

For the administration or supply of

Azithromycin 250mg capsules/tablets

By registered health care professionals for

Chlamydia trachomatis infection

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

PGD NUMBER 09

1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021

2. Medicines practice guideline 2: *Patient group directions*

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care [PGD website FAQs](#)

3. PGD development

Refer to the [NICE PGD competency framework for people developing PGDs](#)

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

4. PGD authorisation

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job Title	Name	Signature	Date
Medical Director			
Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)			

5. PGD adoption by the provider

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job title and organisation	Signature	Date	Applicable or not applicable to area

6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the [NICE PGD competency framework for health professionals using PGDs](#)

	Requirements of registered Healthcare professionals working under the PGD
Qualifications and professional registration	<ul style="list-style-type: none"> Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are permitted staff groups outlined within the current PGD policy Pharmacists must be practising in Manx Care authorised premises i.e. contracted pharmacy premises
Initial training	<ul style="list-style-type: none"> Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD Local training in the use of PGDs
Competency assessment	Staff will be assessed on their knowledge of drugs and clinical assessment as part the competency framework for registered health professionals using PGDs
Ongoing training and competency	The registered health care professionals should make sure they are aware of any changes to the recommendations for this medication; it is the responsibility of the registered health care professionals to keep up to date with continuing professional development. PGD updates will be held every two years

7. Clinical Conditions

Clinical condition or situation to which this PGD applies	Patient either known or suspected of having uncomplicated Chlamydia trachomatis infection, where the patient is unable to take doxycycline
Inclusion criteria	<ul style="list-style-type: none"> • Male or female patient with laboratory confirmed positive genital chlamydia trachomatis diagnosis • Male or female patient who is a sexual contact of any patient in the above group as epidemiological treatment
Exclusion criteria	<ul style="list-style-type: none"> • Under 16 years of age and not assessed as competent using Fraser Guidelines • Hepatic and renal impairment • Patients who are immunocompromised • Patients taking amiodarone, disopyramide, warfarin, nicoumalone anticoagulants, carbamazepine, valproate, cyclosporine, mizolastine, loratidine, desloratidine, terfenadine, pimozone, clozapine, theophylline, aminophylline • Myasthenis Gravis • Allergy to azithromycin • Any female who is pregnant or may be at risk of pregnancy or is breastfeeding • Any patient with nut or soya allergy (check brand)
Cautions (including any relevant action to be taken)	<ul style="list-style-type: none"> • Swallow tablets whole whilst in the clinic setting • Emphasise importance and need for patient's sexual partner(s) to be treated • No sexual intercourse for 1 week. The patient must report any diarrhoea or vomiting within 2 hours of taking the medication as an alternative medication may be required • Advise no sexual intercourse with an untreated partner (even with a condom) • Warn of risk of gastrointestinal upset and skin rash • Advise about risk of candidiasis in patients taking antibiotics • If patient is under 16 years of age the nurse must assess the competence of the patient using the Frazer guidelines and this must be recorded in the case notes. Refer to doctor or senior nurse if unsure of level of competency
Arrangements for referral for medical advice	Patient should be referred to a more experienced clinical practitioner for further assessment
Action to be taken if patient excluded	Patient should be referred to a more experienced clinical practitioner for further assessment

Action to be taken if patient declines treatment	<ul style="list-style-type: none"> • A verbal explanation should be given to the patient on: the need for the medication and any possible effects or potential risks which may occur as a result of refusing treatment • This information must be documented in the patients' health records • Any patient who declines care must have demonstrated capacity to do so • Where appropriate care should be escalated
---	--

8. Details of the medicine

Name, form and strength of medicine	Azithromycin 250mg capsules/tablets
Legal category	Prescription Only Medicine (POM)
Indicate any <u>off-label use</u> (if relevant)	Stat dose is licenced, however further dosing is off-label
Route/method of administration	Oral
Dose and frequency	1g (4 x 250mg tablets/capsules) immediately Plus further dosing of 500mg Once Daily for next 2 days
Quantity to be administered and/or supplied	8 x 250mg tablets/capsules
Maximum or minimum treatment period	One episode of treatment
Storage	Room temperature
Adverse effects	<ul style="list-style-type: none"> • May cause mild gastrointestinal disturbance • May prolong QT interval
Records to be kept	The administration of any medication given under a PGD must be recorded within the patient's medical records

9. Patient information

Verbal/Written information to be given to patient or carer	<ul style="list-style-type: none"> • Verbal information must be given to patients and or carers for all medication being administered under a PGD • Where medication is being supplied under a PGD, written patient information leaflet must also be supplied • A patient information leaflet is available on request
Follow-up advice to be given to patient or carer	If symptoms do not improve or worsen or you become unwell, seek medical advice immediately

10. Appendix A

References
<ol style="list-style-type: none">1. British National Formulary (BNF) available online: https://bnf.nice.org.uk2. Nursing and Midwifery (2018) “The code” available online: https://www.nmc.org.uk3. Current Health Care Professions Council standards of practice4. General Pharmaceutical Council standards5. The General Optical Council6. Electronic medicines compendium available online: https://www.medicines.org.uk

11. Appendix B

Health professionals agreed to practice
<ul style="list-style-type: none">• Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor• A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves